$75.96
3.61% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US6707031075
Symbol
NUVL
Sector
Industry

Nuvalent Inc - Ordinary Shares - Class A Stock price

$75.88
+5.93 8.48% 1M
-15.29 16.77% 6M
-2.40 3.07% YTD
+4.95 6.98% 1Y
+67.82 841.44% 3Y
+57.13 304.69% 5Y
+57.13 304.69% 10Y
Nasdaq, Closing price Tue, May 20 2025
+2.57 3.51%
ISIN
US6707031075
Symbol
NUVL
Sector
Industry

Key metrics

Market capitalization $5.45b
Enterprise Value $4.38b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-322.59m
Free Cash Flow (TTM) Free Cash Flow $-203.80m
Cash position $1.07b
EPS (TTM) EPS $-4.40
P/E forward negative
Short interest 19.75%
Show more

Is Nuvalent Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Nuvalent Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Nuvalent Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 69 69
64% 64%
-
- Research and Development Expense 254 254
95% 95%
-
-323 -323
88% 88%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -323 -323
88% 88%
-
Net Profit -301 -301
107% 107%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nuvalent Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvalent Inc - Ordinary Shares - Class A Stock News

Neutral
PRNewsWire
13 days ago
Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission by mid-year 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC planned for first half of 2025 Pivotal data for neladalkib in TKI pre-treated ALK-positive NSCLC popula...
Neutral
PRNewsWire
21 days ago
CAMBRIDGE, Mass. , April 29, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecul...
Neutral
PRNewsWire
28 days ago
CAMBRIDGE, Mass. , April 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two "Trial in Progress" poster presentations for its novel ALK-selective inhibitor, neladalkib, and novel HER2-selective inhibitor, NVL-330, at the 2025 America...
More Nuvalent Inc - Ordinary Shares - Class A News

Company Profile

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Head office United States
CEO James Porter
Employees 142
Founded 2017
Website www.nuvalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today